As a flagship event under the Healthcare Services track at this year’s CIFTIS, the Forum on Innovation Advancements in Cancer Treatment and Emerging Trends in Drug Development took place on September 14 in Beijing. AmCham China Vice President Claire Ma attended the forum and participated in the roundtable discussion, where she shared in-depth perspectives on opportunities for US-China collaboration in healthcare, industry innovation, and the future of drug development.
Speaking at the roundtable on “Collaborative Mechanisms among Government, Industry, Academia, and Research to Advance Oncology Innovation”, Ma emphasized that collaboration is not just an academic concept, it is essential for translating innovation into real-world outcomes.
She noted that US-China collaboration in oncology innovation has recently gained momentum, spanning licensing, R&D, clinical trials, and commercialization. With China’s strengths in clinical research and digitalization, and the US’s leadership in basic research and global integration, the two sides have the potential to enhance efficiency, reduce costs, and accelerate patient access to cutting-edge treatments. Ma also noted that going forward, AmCham China will continue to serve as a bridge, advocating for policy improvements, fostering industry dialogue, and supporting capacity building, to advance cross-border cooperation and help bring more breakthrough therapies to patients in China.